Continuing Education Activity

Acute-on-chronic liver failure (ACLF) is a distinct clinical syndrome marked by sudden hepatic decompensation in patients with underlying chronic liver disease, resulting in rapid development of extrahepatic organ failures and high short-term mortality. This condition represents a dynamic intersection of liver and systemic failure, with varying definitions and criteria across global societies. Each society influences diagnostic thresholds, prevalence, and clinical trial design. Understanding these frameworks and validated grading systems is essential for early prognostication and clinical decision-making.

This continuing education activity provides a comprehensive, evidence-based overview of ACLF, designed to enhance the clinical competence of healthcare professionals managing this high-risk population. Learners will gain insight into precipitating factors, diagnostic evaluation, and prognostic scoring systems, as well as current guidelines for management, ranging from infection control to the use of vasopressors, renal replacement therapy, and consideration of liver support and transplantation. The activity also explores preventive strategies and emerging therapies while highlighting the critical importance of interprofessional collaboration, including hepatology, critical care, infectious diseases, pharmacy, nutrition, and nursing, to ensure cohesive, protocol-driven care and improved patient outcomes.

Objectives:

• Identify patients at risk for acute-on-chronic liver failure based on clinical presentation and known precipitants in chronic liver disease.
• Assess organ dysfunction using validated grading systems.
• Implement guideline-recommended supportive measures, including volume management, vasopressor use, and nutritional support.
• Coordinate follow-up care and preventive strategies such as vaccination, alcohol abstinence, and avoidance of hepatotoxic agents.

Access free multiple choice questions on this topic.

Introduction

Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by sudden hepatic decompensation observed in patients with preexisting chronic liver disease (CLD). This condition is associated with 1 or more extrahepatic organ failures and increased risk of mortality.[1][2][3][4] Currently, there are 3 primary definitions of ACLF, each influenced by geographical perspectives. The Asian Pacific Association for the Study of the Liver (APASL) emphasizes a liver-centric pathogenesis and includes patients with CLD—even without cirrhosis—as the chronic component and identifies patients in the early phase of the disease.

In contrast, the North American Consortium for the Study of End-Stage Liver Disease (NASCELD) focuses on patients with cirrhosis who develop extrahepatic organ failures. The European Association for the Study of the Liver (EASL) takes a broader view, including both hepatic and extrahepatic insults and considering failure in any of 6 organ systems. Additionally, a fourth definition has been proposed by the World Gastroenterology Organization (WGO), which seeks to integrate key elements from the 3 regional models of ACLF. This integrative approach aims to provide a more universally applicable framework for diagnosis and research across diverse patient populations.

The common factor in all definitions is the high short-term mortality, which distinguishes these patients. Despite variations in diagnostic criteria, all definitions consistently recognize the high mortality associated with ACLF, particularly among patients with multiple organ failures. Whether mortality should be included in the nosologic definition remains controversial. Nonetheless, all societies concur that ACLF represents a distinct clinical entity with uniquely poor early outcomes. However, they identify these patients at different stages in the syndrome's progress. The universally accepted consensus definition of the syndrome remains an unmet need.[5]

The initial classification of ACLF divided the condition into 3 types.[6] Type-A ACLF refers to the acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF describes acute decompensation in patients with cirrhosis, while type-C ACLF involves acute deterioration of patients with previously decompensated cirrhosis. However, with the evolving definitions of ACLF across different societies, this classification system's clinical applicability has become a subject of ongoing debate.

Etiology

The etiology of ACLF typically involves a precipitating event occurring in the setting of a preexisting liver condition. Hepatic triggers include alcohol-associated hepatitis, drug-induced liver injury, viral hepatitis (A, B, C, D, and E), hypoxic injury, or liver-related procedures, including transjugular intrahepatic portosystemic shunt placement. Extrahepatic causes are primarily bacterial infections and major surgical interventions. Notably, in approximately 40% to 50% of cases, no identifiable precipitating event is found, and these patients are categorized as having an unrecognized trigger for ACLF.[7][8][9]

The precipitating event of ACLF shows geographical variation, similar to the etiology of acute liver failure. In Western countries, acute alcohol-related liver injury and bacterial infections are the most common triggers. In contrast, in Asia, the predominant causes include reactivation of chronic hepatitis B, acute hepatitis A and E infections, in addition to acute alcohol injury and bacterial infections. This variation is partly attributable to differences in the definitions used to diagnose ACLF, particularly the APASL definition used in Asia, which includes only hepatic insults. Initially, infections were considered a consequence of ACLF rather than a trigger. However, the latest guidelines now recognize infections as an important precipitating factor in developing liver failure.[5]

Epidemiology

According to the American Association for the Study of Liver Diseases (AASLD), the 28-day mortality for patients with ACLF ranges from 30% to 50%, depending on the number and severity of organ failures.[10] Compared to other more common causes of hospitalization in the United States, the healthcare burden per patient with ACLF is significantly higher. The mean cost of hospitalization for patients with ACLF is 3 times greater than the cost of patients hospitalized with cirrhosis, and 5 times higher than the cost of patients hospitalized with congestive heart failure.[11][12]

Although outcomes have improved over time, ACLF remains associated with high mortality. The estimated mortality rate decreased from 65% in 2001 to 50% in 2011. According to the European Association for the Study of Liver-Chronic-Liver Failure (EASL-CLIF) Consortium, the current global mortality rate ranges between 30% and 50%. In the United States, data from the North-American Consortium for the Study of End-Stage Liver Disease (NACSELD) show mortality rates of 27%, 49%, 64%, and 77% in infected decompensated patients with 1, 2, 3, or 4 organ failures, respectively.[13][14] Patients discharged following admission for ACLF have an approximately 30% readmission rate within 30 days. The high readmission rate highlights the need for improved post-discharge care and closer monitoring to reduce recurrence and improve long-term outcomes.[15][16]

Pathophysiology

The pathophysiology of ACLF is based on the understanding that an acute precipitating event in a patient with a chronic liver condition causes hepatocellular injury, triggering a cascade of inflammatory cytokines and resulting in further hepatic injury, particularly impaired hepatocyte regeneration. The resulting immune dysfunction and hepatic decompensation increase the patient's vulnerability to infections, ultimately contributing to multiple organ failure and high mortality.

Systemic inflammation, characterized by elevated leukocytosis, cytokines, and chemokines (including interleukin-6 and interleukin-8), is commonly observed in patients with ACLF. This inflammatory response is typically absent in patients with compensated cirrhosis without ACLF. Bacteria-induced pathogen-associated molecular patterns (PAMPS) and virulence factors activate transcription factors that drive cytokine expression in the inflammatory cascade. In addition, endogenous inducers of inflammation, known as damage-associated molecular patterns (DAMPs)—released from injured or necrotic hepatocytes—also activate inflammatory pathways. These DAMPs interact with Toll-like receptors (TLRs) to amplify the immune response. This immunopathology plays a role in causing tissue and organ damage, ultimately leading to multiple organ failure in patients with ACLF.[17]

History and Physical

A thorough history is essential to identify potential precipitating factors for acute hepatic decompensation. Information should be gathered from the patient’s medical records, the patient, or their family. This includes a known history of chronic liver disease and the degree of fibrosis or cirrhosis, any prior episodes of hepatic decompensation, and the presence of other relevant chronic health conditions. Determining the timeline and nature of presenting symptoms, such as systemic features, fluid overload, gastrointestinal bleeding, abdominal pain, and altered mental status is also important. Inquiries should be made regarding toxic habits or high-risk behaviors, such as alcohol use or intravenous drug use.

Any recent changes in medications or ingestion of potentially hepatotoxic substances, including herbal remedies, sedatives, or analgesics, should be noted. Recent travel history and any recent surgical procedures, particularly transjugular intrahepatic portosystemic shunt placement, are also relevant. On physical examination, findings may include hypotension, altered mental status, jaundice, asterixis, fever (which may suggest an infectious etiology), right upper quadrant pain or tenderness, nausea, and other signs indicative of liver failure.[18]

Evaluation

Patients with ACLF typically present with features of acute hepatic decompensation. Common laboratory abnormalities include a prolonged international normalized ratio of 1.5 or greater, elevated bilirubin and aminotransferases, thrombocytopenia with anemia, hypoglycemia, elevated ammonia levels, and evidence of acute kidney injury (AKI), often reflected by increased serum creatinine and electrolyte imbalances.[19][20][21][22] Among extrahepatic organ failures, the kidney is the most commonly affected in the ACLF. Therefore, it is essential to differentiate the underlying etiologies of AKI, which may include prerenal AKI, hepatorenal syndrome, acute tubular injury, and cholemic nephropathy.[23]

Imaging studies may be necessary to support clinical examination findings and assess for infection or organ failure. Based on clinical suspicion, imaging of the brain, chest, abdomen, and pelvis should be considered. Abdominal imaging is essential to evaluate for portal hypertension, hepatocellular carcinoma, vascular thrombosis, lymphadenopathy, and splenomegaly. An abdominal sonogram with Doppler is particularly useful in patients with renal dysfunction or suspected vascular thrombosis. Brain imaging with computed tomography or magnetic resonance imaging can help rule out structural causes of altered mental status. In contrast, chest imaging is valuable in identifying pulmonary edema, pneumonia, or other thoracic complications. 

The grading and classification of ACLF vary across major hepatology societies, reflecting differences in pathophysiological focus and regional disease patterns. The 3 major ACLF grading systems include EASL-CLIF, NACSELD, and APAS (AARC score). Each system uses different clinical parameters and serves distinct purposes in patient care, depending on regional practices and patient profiles (see Table. Comparison of ACLF Grading Systems). Understanding these distinctions is essential for accurate diagnosis, risk stratification, and management of ACLF.  

Table

Table. Comparison of ACLF Grading Systems.

AARC, American Association for Respiratory Care; ACLF, acute-on-chronic liver failure; APASL, Asian Pacific Association for the Study of the Liver; EASL-CLIF, European Association for the Study of the Liver—Chronic Liver Failure Consortium; INR, International Normalized Ratio; NACSELD, North American Consortium for the Study of End-Stage Liver Disease 

While the NACSELD system focuses exclusively on extrahepatic organ failures, its “grading” is effectively based on the number of organ failures. The APASL approach centers on liver injury and employs a numerical score to risk-stratify patients and predict survival, particularly in the context of liver transplantation. In contrast, the EASL-CLIF system captures a broader spectrum of patients and provides detailed risk stratification across varying severities of organ failure.[5]

Treatment / Management

Managing ACLF involves preventing precipitating factors that lead to acute hepatic decompensation, providing supportive care, and initiating specific therapies early. Management also includes preventing and managing complications, assessment of prognosis, and evaluation for liver support, including possible need for liver transplantation. All patients should be hospitalized, preferably at a center with the necessary facilities and expertise for liver transplantation.[24][25]

Prevention of Precipitating Factors Leading to Acute Hepatic Decompensation

While managing ACLF, it is essential to maintain a high index of suspicion for infection. Clinicians should evaluate for potential sources of infection and initiate appropriate treatment as early as possible; early intervention is key to improving outcomes. Sustained viral suppression of hepatitis B and C should be a priority to prevent ongoing liver injury and further hepatic decompensation. Antiviral therapy plays a crucial role in managing the underlying chronic liver disease and reducing the risk of ACLF progression.[26] In patients diagnosed with spontaneous bacterial peritonitis, intravenous albumin should be administered to prevent the development of accelerated renal dysfunction, a hallmark of hepatorenal physiology. However, current evidence does not support the use of intravenous albumin in other types of bacterial infections.[27]

Further, for patients with severe acute alcohol-associated hepatitis, prognostic scoring tools such as the Maddrey Discriminant Function and Model for End-Stage Liver Disease score should be used to guide treatment decisions. These scores help determine the severity of the disease and the need for specific therapies. Preventing AKI is also a critical component of management in this setting.[28] In patients with septic shock, a personalized and carefully monitored approach should be applied. These patients should be stabilized and evaluated for liver transplantation after recovery, as many progress to grade 3 ACLF and have poor survival without transplant intervention.[29]

Supportive Care

• Assess hemodynamic stability and determine the need for intravenous fluid while maintaining acid-base balance and correcting electrolyte abnormalities. Vasopressors should be used to maintain a mean arterial pressure of 75 mm Hg or greater to ensure adequate renal and cerebral perfusion. Serum lactate, a component of the AARC score for ACLF, is an important prognostic marker.
• Monitor hematocrit closely, as patients often have coagulopathy and impaired platelet function, placing them at risk for bleeding. Blood products such as platelets and fresh frozen plasma should be administered in cases of active bleeding.
• Evaluate for hepatic encephalopathy and protect the airway in patients showing signs of neurologic deterioration. Intubation may be necessary in cases of advanced encephalopathy, and protocols should be followed to prevent cerebral edema.
• Ensure adequate nutrition by providing 1 to 1.5 grams of protein per kilogram of body weight per day. Monitor for hypoglycemia and aim to maintain blood glucose levels between 160 and 200 mg/dL.
• Discontinue all home medications unless they are deemed essential to continue during hospitalization. Particular attention should be paid to potentially hepatotoxic drugs, sedatives, and nephrotoxic agents, which may worsen liver or kidney function in the setting of ACLF.

Specific Treatment when Etiology is Known   

• Patients with hepatitis A- or E-associated ACLF should receive supportive care, as there are currently no effective antiviral therapies for these infections. Management focuses on monitoring for complications and maintaining organ support.[30][31]
• For patients with acute hepatitis C or reactivation of chronic hepatitis C, appropriate antiviral therapy should be initiated. The choice of regimen depends on prior treatment history and the patient’s overall clinical status.
• Patients experiencing acute hepatitis B or reactivation of chronic hepatitis B should be started on nucleos(t)ide analogs. Early antiviral intervention can help reduce viral load and improve outcomes.
• In cases where ACLF is triggered by acute decompensation of Wilson disease or hepatic vein thrombosis (such as Budd-Chiari syndrome), liver transplantation should be considered promptly. These conditions carry a poor prognosis with medical therapy alone.

Management of Complications

Every effort should be made to prevent the progression to multiple organ dysfunction, as it significantly worsens the prognosis in ACLF. Early recognition and aggressive management of complications are key to improving patient outcomes. 

• Kidney failure may result from hypovolemia, acute tubular necrosis, or hepatorenal syndrome.
• Vasopressor therapy with norepinephrine or dopamine is indicated in severe hypotension.
• Renal replacement therapy may serve as a bridge to liver transplantation, with continuous renal replacement therapy preferred over intermittent hemodialysis in critically ill individuals.
• Sepsis, including aspiration pneumonia, should be promptly treated with a broad-spectrum antibiotic.
• Blood, sputum, and urine surveillance cultures are recommended for all patients with ACLF to guide therapy.

Metabolic disturbances are common and require targeted management.

• Hypoglycemia, due to impaired glycogen storage and gluconeogenesis, should be treated with continuous infusions of 10% or 20% glucose.[10]
• Hypophosphatemia, related to adensine triphosphate depletion from hepatocyte necrosis, requires aggressive phosphate repletion.
• Alkalosis may occur from hyperventilation, while acidemia with a pH below 7.3 is associated with 95% mortality in acetaminophen overdose if transplantation is not performed.[10] 
• Hypoxemia may develop due to aspiration, ARDS, or pulmonary hemorrhage.
• Patients with encephalopathy beyond grade 2 should be intubated to protect the airway. Seizure-like activity can be managed with phenytoin or benzodiazepines.

Encephalopathy is a hallmark of ACLF and should be closely monitored. In patients with grade 3 encephalopathy or higher, head computed tomography imaging is recommended to assess for cerebral edema or intracranial bleeding.

• Coagulopathy is frequently present but does not often lead to spontaneous bleeding.
• Routine correction is unnecessary unless there is active bleeding or a planned invasive procedure.
• If clinically indicated, transfusion of platelets, fresh frozen plasma, or cryoprecipitate may be used.
• Recombinant factor VII should be used cautiously due to the risk of thrombosis.
• Intravenous vitamin K may be administered slowly if nutritional deficiency or prolonged cholestasis is suspected.

Liver Support and Transplantation

Grading ACLF during the hospital stay helps physicians assess whether a patient will likely recover or require a liver transplant. Although liver transplantation remains the only definitive treatment for ACLF, no standardized selection criteria currently exist.[10][32] Moreover, active infections disqualify nearly half of the patients from transplant eligibility. Among those listed, only 10% to 25% receive a transplant, while 50% to 75% die while waiting.[33]

Extracorporeal liver-assist devices have been used in clinical trials in patients as a potential treatment for ACLF. These devices aim to support detoxification and restore synthetic liver functions. Bioartificial liver support systems have been developed, including porcine hepatocyte-based tumor hepatocyte system, Vitalal Therapies ELAD, and Alliqua HepatAssist 2000. However, results from recent multicenter trials have not demonstrated a survival benefit. Newer extracorporeal systems are currently under investigation.[34] The role of plasma exchange in ACLF remains controversial, with a recent meta-analysis showing no significant survival advantage.[35]

Differential Diagnosis

ACLF is a distinct clinical syndrome and should be carefully differentiated from other liver-related and systemic conditions, including:

• Acute decompensation of cirrhosis 
• Nonacute decompensation of cirrhosis 
• Acute liver failure due to multiple etiologies (eg, drug-induced liver injury, acute viral hepatitis)
• Sepsis and multiple organ dysfunction syndrome (note that under the EASL-CLIF definition, a diagnosis of ACLF does not require elevated bilirubin or INR. Therefore, a high degree of clinical suspicion and thorough understanding of the diagnostic criteria are critical)
• Acute hepatitis from various etiologies (drug-induced liver injury, ischemic hepatitis, reactivation hepatitis B virus)

Prognosis

The CLIF Organ Failure score is a valuable tool for predicting mortality in patients with ACLF. Mortality risk increases proportionally with the number of organ failures. A CLIF score above 64 warrants immediate evaluation for liver transplantation. Importantly, the underlying etiology of the precipitating event does not significantly influence prognosis. 

Infections are the most common etiology of ACLF and are associated with poorer outcomes, as infected patients are often delisted from transplant consideration. Among all organ failures, respiratory failure is linked to the highest mortality. ACLF is a dynamic syndrome that can improve, worsen, or follow a protracted course, offering a potential window for liver transplantation in appropriate candidates. Close clinical progression and organ function monitoring are essential to guide timely intervention.

Complications

Major complications of ACLF include the following:

• AKI
• Hepatic encephalopathy
• Sepsis (bacterial and fungal)
• Circulatory failure or vasoplegic shock
• Respiratory failure
• Gastrointestinal hemorrhage 
• Coagulation failure and bleeding manifestations

Deterrence and Patient Education

The prevention of ACLF development in patients with known chronic liver disease centers on avoiding known precipitants. Early identification and management of risk factors can significantly reduce the likelihood of acute decompensation and improve overall prognosis. First, hepatotoxic agents should be strictly avoided. This includes limiting acetaminophen use to less than 2 grams per day, avoiding nonsteroidal anti-inflammatory drugs and high-risk antibiotics, and steering clear of unsupervised herbal or bodybuilding supplements.

Regular medication reconciliation is essential to detect early signs of drug-induced liver injury. Vaccination against viral hepatitis is critical. Patients should receive the full 2-dose hepatitis A vaccine and complete the hepatitis B virus (HBV) vaccination series, with postvaccine anti-hepatitis B confirmation. In patients with cirrhosis, higher or accelerated dosing may be considered.

Absolute alcohol abstinence is strongly recommended. Even small amounts of alcohol can accelerate disease progression and significantly increase the risk of ACLF. Patients should receive counseling and relapse-prevention therapy when appropriate. Finally, recognized precipitants should be minimized. Prompt treatment of infections or gastrointestinal bleeding is essential. Adherence to nonselective β-blockers, regular endoscopic surveillance, and antiviral prophylaxis during immunosuppression are important strategies to prevent HBV reactivation and associated complications.

Pearls and Other Issues

Key facts to keep in mind about ACLF include the following:

• ACLF is a sudden deterioration in liver function in a patient with known chronic liver disease, often triggered by infection, alcohol use, hepatitis B or C reactivation, or drug-induced liver injury.
• ACLF is distinct from acute liver failure, which occurs in patients without preexisting liver disease.
• Standard clinical features include jaundice, hepatic encephalopathy, coagulopathy (elevated INR), ascites, kidney injury, and signs of systemic inflammation.
• Kidney failure is the most frequent organ failure in ACLF and is a key predictor of poor outcomes.
• Infections are the most common precipitating factor and should be promptly identified and treated.
• Diagnosis involves laboratory findings such as elevated bilirubin, INR, creatinine, ammonia, and leukocytosis; imaging may help identify precipitating causes like infection or vascular thrombosis.
• Prognosis is assessed using scoring systems like EASL-CLIF (grades based on  number of organ failures), NACSELD (extrahepatic focus), and APASL (liver-centered with a numerical score).
• Management includes treating the underlying trigger, supportive care with fluids and nutrition, albumin for spontaneous bacterial peritonitis, antivirals for hepatitis B or C, and avoiding hepatotoxic drugs.
• Patients with hepatic encephalopathy grade ≥3 may require intubation to protect the airway and prevent aspiration.
• Early referral to a transplant center is critical, as liver transplantation is the only definitive treatment for ACLF.
• ACLF has high short-term mortality, especially with ≥2 organ failures or in the presence of sepsis or respiratory failure.
• Prevention includes avoiding alcohol, hepatotoxic medications, and infections; ensuring vaccination for hepatitis A and B; and managing chronic liver disease with regular monitoring and prophylaxis.

Enhancing Healthcare Team Outcomes

ACLF is a serious condition associated with high morbidity and mortality. Optimal management requires an interprofessional team, including a specialty-trained nurse, internist, hepatologist, nephrologist, neurologist, transplant surgeon, radiologist, pathologist, infectious disease specialist, and intensivist. Current treatment focuses on supportive care and addressing the underlying precipitating factors, as no curative medical therapy exists. The prognosis remains guarded for most patients. Liver transplantation can significantly improve survival but carries a risk of severe complications.[7][36]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Praktiknjo M, Clees C, Pigliacelli A, Fischer S, Jansen C, Lehmann J, Pohlmann A, Lattanzi B, Krabbe VK, Strassburg CP, Arroyo V, Merli M, Meyer C, Trebicka J. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. Clin Transl Gastroenterol. 2019 Apr;10(4):e00025. [PMC free article: PMC6602782] [PubMed: 30939488]

2.

Cai JJ, Wang K, Jiang HQ, Han T. Characteristics, Risk Factors, and Adverse Outcomes of Hyperkalemia in Acute-on-Chronic Liver Failure Patients. Biomed Res Int. 2019;2019:6025726. [PMC free article: PMC6415283] [PubMed: 30937312]

3.

Wilde B, Katsounas A. Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis. Mediators Inflamm. 2019;2019:7537649. [PMC free article: PMC6410448] [PubMed: 30930689]

4.

Patil V, Jain M, Venkataraman J. Paracentesis-induced acute kidney injury in decompensated cirrhosis - prevalence and predictors. Clin Exp Hepatol. 2019 Mar;5(1):55-59. [PMC free article: PMC6431093] [PubMed: 30915407]

5.

Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cárdenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Zhongping D, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia J, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win KM, Suk KT, Devadas K, Lesmana LA, Kamani L, Premkumar M, Niriella MA, Al Mahtab M, Yuen MF, Sayed MH, Alla M, Wadhawan M, Sharma MK, Sahu M, Prasad M, Muthiah MD, Schulz M, Bajpai M, Reddy MS, Praktiknjo M, Yu ML, Prasad M, Sharma M, Elbasiony M, Eslam M, Azam MG, Rela M, Desai MS, Vij M, Mahmud N, Choudhary NS, Marannan NK, Ormeci N, Saraf N, Verma N, Nakayama N, Kawada N, Oidov Baatarkhuu, Goyal O, Yokosuka O, Rao PN, Angeli P, Parikh P, Kamath PS, Thuluvath PJ, Lingohr P, Ranjan P, Bhangui P, Rathi P, Sakhuja P, Puri P, Ning Q, Dhiman RK, Kumar R, Vijayaraghavan R, Khanna R, Maiwall R, Mohanka R, Moreau R, Gani RA, Loomba R, Mehtani R, Rajaram RB, Hamid SS, Palnitkar S, Lal S, Biswas S, Chirapongsathorn S, Agarwal S, Sachdeva S, Saigal S, Kumar SE, Violeta S, Singh SP, Mochida S, Mukewar S, Alam S, Lim SG, Alam S, Shalimar, Venishetty S, Sundaram SS, Shetty S, Bhatia S, Singh SA, Kottilil S, Strasser S, Shasthry SM, Maung ST, Tan SS, Treeprasertsuk S, Asthana S, Manekeller S, Gupta S, Acharya SK, K C S, Maharshi S, Asrani S, Dadhich S, Taneja S, Giri S, Singh S, Chen T, Gupta T, Kanda T, Tanwandee T, Piratvishuth T, Spengler U, Prasad VGM, Midha V, Rakhmetova V, Arroyo V, Sood V, Br VK, Wong VW, Pamecha V, Singh V, Dayal VM, Saraswat VA, Kim W, Jafri W, Gu W, Jun WY, Qi X, Chawla YK, Kim YJ, Shi Y, Abbas Z, Kumar G, Shiina S, Wei L, Omata M, Sarin SK., APASL-ACLF Research Consortium (AARC) for APASL-ACLF working party. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int. 2025 Feb;19(1):1-69. [PMC free article: PMC11846769] [PubMed: 39961976]

6.

Mu X, Tong J, Xu X, Chen J, Su H, Liu X, Pang F, Zhai X, Wang L, Wang Y, Guan C, Wang F, Hu J. World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101548. [PubMed: 33554865]

7.

Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? Liver Transpl. 2019 Jun;25(6):946-959. [PubMed: 30900368]

8.

Lopes D, Samant H. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Hepatic Failure(Archived) [PubMed: 30855815]

9.

Thongprayoon C, Kaewput W, Thamcharoen N, Bathini T, Watthanasuntorn K, Lertjitbanjong P, Sharma K, Salim SA, Ungprasert P, Wijarnpreecha K, Kröner PT, Aeddula NR, Mao MA, Cheungpasitporn W. Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis. J Clin Med. 2019 Mar 17;8(3) [PMC free article: PMC6463182] [PubMed: 30884912]

10.

Karvellas CJ, Bajaj JS, Kamath PS, Napolitano L, O'Leary JG, Solà E, Subramanian R, Wong F, Asrani SK. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology. 2024 Jun 01;79(6):1463-1502. [PubMed: 37939273]

11.

Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Chaiprasert A, Phaosawasdi K, Treeprasertsuk S. Health care burden and mortality of acute on chronic liver failure in Thailand: a nationwide population-based cohort study. BMC Health Serv Res. 2022 Feb 07;22(1):156. [PMC free article: PMC8819862] [PubMed: 35125103]

12.

Asrani SK, Kouznetsova M, Ogola G, Taylor T, Masica A, Pope B, Trotter J, Kamath P, Kanwal F. Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. Gastroenterology. 2018 Sep;155(3):719-729.e4. [PubMed: 29802851]

13.

Avolio AW, Gaspari R, Teofili L, Bianco G, Spinazzola G, Soave PM, Paiano G, Francesconi AG, Arcangeli A, Nicolotti N, Antonelli M. Postoperative respiratory failure in liver transplantation: Risk factors and effect on prognosis. PLoS One. 2019;14(2):e0211678. [PMC free article: PMC6370207] [PubMed: 30742650]

14.

Mattos ÂZ, Mattos AA. Letter to the Editor: Acute-on-Chronic Liver Failure: Conceptual Divergences. Hepatology. 2019 Sep;70(3):1076. [PubMed: 30864173]

15.

Hernaez R, Kramer JR, Liu Y, Tansel A, Natarajan Y, Hussain KB, Ginès P, Solà E, Moreau R, Gerbes A, El-Serag HB, Kanwal F. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 Apr;70(4):639-647. [PubMed: 30590100]

16.

Mumtaz K, Issak A, Porter K, Kelly S, Hanje J, Michaels AJ, Conteh LF, El-Hinnawi A, Black SM, Abougergi MS. Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database. Hepatology. 2019 Aug;70(2):630-639. [PubMed: 30218583]

17.

Moreau R, Gao B, Papp M, Bañares R, Kamath PS. Acute-on-chronic liver failure: A distinct clinical syndrome. J Hepatol. 2021 Jul;75 Suppl 1:S27-S35. [PubMed: 34039489]

18.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025 Aug;83(2):453-501. [PubMed: 40348684]

19.

Artzner T, Michard B, Besch C, Levesque E, Faitot F. Liver transplantation for critically ill cirrhotic patients: Overview and pragmatic proposals. World J Gastroenterol. 2018 Dec 14;24(46):5203-5214. [PMC free article: PMC6295835] [PubMed: 30581269]

20.

Chinese Society of Hepatology, Chinese Medical Association. [Guidelines for the diagnosis and management of hepatic encephalopathy in cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2018 Oct 20;26(10):721-736. [PMC free article: PMC12813421] [PubMed: 30481878]

21.

Steve RJ, Gnanadurai FJ, Anantharam R, Jeyaseelan V, Zachariah UG, Goel A, Chundamannil EE, Abraham P. Expanded diagnostic approach to hepatitis E virus detection in patients with acute-on-chronic liver failure: A pilot study. Indian J Med Microbiol. 2018 Jul-Sep;36(3):391-396. [PubMed: 30429393]

22.

Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Ibañez-Samaniego L, Silva-Junior G, Martinez J, Genescà J, Bureau C, Trebicka J, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud LL, Noronha Ferreira C, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Robic MA, Conejo I, Catalina MV, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, Garcia-Pagán JC., International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. Hepatology. 2019 Jan;69(1):282-293. [PubMed: 30014519]

23.

Girish V, Maiwall R. Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum. Clin Mol Hepatol. 2025 Jul;31(3):730-752. [PMC free article: PMC12260623] [PubMed: 40138802]

24.

Raices M, Czerwonko ME, Ardiles V, Boldrini G, D'Agostino D, Marcó Del Pont J, Pekolj J, Mattera J, Brandi C, Ciardullo M, de Santibañes E, de Santibañes M. Short- and Long-Term Outcomes After Live-Donor Transplantation with Hyper-Reduced Liver Grafts in Low-Weight Pediatric Recipients. J Gastrointest Surg. 2019 Dec;23(12):2411-2420. [PubMed: 30887299]

25.

Lum EL, Cárdenas A, Martin P, Bunnapradist S. Current Status of Simultaneous Liver-Kidney Transplantation in the United States. Liver Transpl. 2019 May;25(5):797-806. [PubMed: 30861294]

26.

Bektas E, Yilmaz A, Kikili CI, Nuriyev K, Istemihan Z, Senkal IV, Imanov Z, Cavus B, Cifcibasi Ormeci A, Akyuz F, Demir K, Besisik SF, Kaymakoglu S. Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real-World Cohort. Int J Hepatol. 2025;2025:9632839. [PMC free article: PMC12014250] [PubMed: 40265082]

27.

Angeli P, Labenz C, Piano S, Juanola A, Krag A, Caraceni P, Trebicka J, Maiwall R, Singh V, Pose E, Gambino C, Marciano S, Galle PR, Sarin SK, Ginès P, Kamath PS. Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus. J Hepatol. 2025 Sep;83(3):800-802. [PubMed: 40250764]

28.

Girish V, Maiwall R. Editorial: Solving the acute kidney injury puzzle in alcohol-associated hepatitis-Challenges and insights. Aliment Pharmacol Ther. 2024 Oct;60(7):963-964. [PubMed: 39225450]

29.

Girish V, Maiwall R. Revisiting septic shock in cirrhosis: a call for personalized management. Expert Rev Gastroenterol Hepatol. 2024 Dec;18(12):795-813. [PubMed: 39744868]

30.

Girish V, Grant LM, Sharma B, Koirala J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 6, 2025. Hepatitis E. [PubMed: 30335311]

31.

Girish V, Grant LM, John S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 6, 2024. Hepatitis A. [PubMed: 29083664]

32.

Belli LS, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polak WG, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, Volpes R, Karam V, Adam R, Faitot F, Rabinovich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Fondevila C, Michard B, Coilly A, Meszaros M, Poinsot D, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Jalan R., ELITA/EF-CLIF working group. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021 Sep;75(3):610-622. [PubMed: 33951535]

33.

Schulz MS, Gu W, Schnitzbauer AA, Trebicka J. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int. 2022;35:10108. [PMC free article: PMC9099355] [PubMed: 35572467]

34.

Ballester MP, Elshabrawi A, Jalan R. Extracorporeal liver support and liver transplantation for acute-on-chronic liver failure. Liver Int. 2025 Mar;45(3):e15647. [PMC free article: PMC11815617] [PubMed: 37312660]

35.

Kumar SE, Sithamparapillai K, Choudhury AK, Bharadwaj PK, Trebicka J, Karvellas CJ, Arab JP, Premkumar PS, Eapen CE, Goel A. Therapeutic Plasma Exchange in Patients With Acute-On-Chronic Liver Failure Improves Survival-An Updated Meta-Analysis. Liver Int. 2025 May;45(5):e70018. [PubMed: 40265656]

36.

Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T. Karnofsky Performance Status Following Liver Transplantation in Patients With Multiple Organ Failures and Probable Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2020 Jan;18(1):234-241. [PubMed: 30885883]

Disclosure: Vishnu Girish declares no relevant financial relationships with ineligible companies.

Disclosure: Omar Mousa declares no relevant financial relationships with ineligible companies.

Disclosure: Kunzah Syed declares no relevant financial relationships with ineligible companies.

Disclosure: Savio John declares no relevant financial relationships with ineligible companies.